After the first generation of calcimimetics, which is represented by phenylalkylamine derivatives, such as NPS R-568 and NPS R-467 [122], the second generation reached the clinic: cinacalcet is the only CaR modulator currently used in clinical practice to reduce parathyroid glands activity in patients under dialysis for end-stage renal disease [123,124,125]. Here, CASR is linked to chronic kidney disease.